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Elmadhun et al Evolving Technology/Basic Scienceprotein kinase also activates the reperfusion injury salvage
kinase pathway and initiates ischemic preconditioning.10
Metformin-mediated AMPK activation has also been
shown to increase ATP generation and attenuates cardio-
myocyte apoptosis.17 Thus, metformin effectively precon-
ditions the heart against ischemia–reperfusion injury by
activating AMPK. Our findings demonstrate that chronic
treatment with metformin in the context of metabolic syn-
drome and myocardial ischemia dramatically upregulate
insulin signaling, which is at the crossroads of known
metabolic and survival benefits of metformin.E
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Dr Harold L. Lazar (Boston, Mass). I enjoyed your presenta-
tion and thank you for allowing me to see the manuscript in ad-
vance. I just have a couple of small questions to ask: How did
you choose the dose of metformin? Five hundred milligrams fed
orally twice a day is considered a smaller dose. Do you think there
is any dose–response relationship with what you saw?
Dr Elmadhun. We chose that dose based on human dosing.
And actually, these animals are smaller—they’re about 30 kg—
and so we anticipate that these levels would be synonymous
with what we find in humans.
Dr Lazar. I’m also interested—. Did you think about giving the
metformin prior to the ischemia for a period of time? I’m just won-
dering if it would have been interesting to see what the signaling
pathways, the expression of GLUT4, might have been increased
if you had given it prior to performing the period of ischemia.
Dr Elmadhun. Certainly, that would be interesting to look at
in future studies–to administer metformin prior to chronic ische-
mia or in an acute ischemia-reperfusion model. In other studies,
that would be interesting to do, too. As opposed to a chronic
model of ischemia, as the prior speakers discussed, an acute re-
perfusion injury would also be an interesting thing to look at as
well.
Dr Lazar. Have you also considered looking at the effects of
metformin in other cardioprotective agents such as endothelial ni-
tric oxide synthase, which is also mediated through many of these
pathways?
Dr Elmadhun. Yes. Actually, I just presented that data at the
Atherosclerosis, Thrombosis, Vascular Biology last week, and
we did find that there were other cardioprotective mechanisms
by increasing cell protective proteins and also reduction or inhibi-
tion of apoptosis-related proteins. We did find that there was upre-
gulation of phosphorylated endothelial nitric oxide synthase in the
ischemic territories.
Dr Lazar.And finally, did you look at any changes in either he-
modynamic function or cardiac function contractility in this
model?
Dr Elmadhun.We did. We looked at contractility and hemody-
namic parameters, and we did not find any differences among
groups.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). I would
like to ask you a question about study design. I am sure it isrdiovascular Surgery c Volume 145, Number 1 265
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Sexpensive to do these kinds of studies, but I was really struck by the
figure where you showed activation of the AMPK in the animals
that received metformin where there was actually relatively little
difference between the normal animals and the metabolic syn-
drome animals. What would you think, or maybe other people
have already examined it, would be the effect of metformin on
animals without metabolic syndrome?266 The Journal of Thoracic and Cardiovascular SurgDr Elmadhun. Previous studies have looked at this—looking at
just animals with a regular diet and supplemented with metformin
to prove the fact that patients don’t need to have diabetes mellitus
with metabolic syndrome and tolerate metformin—and they have
found that one of the mechanisms is to trick cells into believing
that they are starved and increasing the AMP-to-ATP ratio, which
thereby activates AMPK.ery c January 2013
